Above Food Ingredients Inc.: Above Food Provides Update on Nasdaq Listing Review Process and Engages Dickson Wright to Represent Company in Appeal

Above Food Ingredients Inc. (OTC: ABVEF) said it has hired Dickinson Wright PLLC to represent it in an appeal before Nasdaq’s Listing and Hearing Review Council after a prior delisting determination. The company plans to update Nasdaq on progress toward overdue periodic filings, including its Form 20-F for the year ended Jan. 31, 2026.

Original reporting
Published Jul 17, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 2:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefRegulation
Primary signal
$ABVEF
Neutral
medium confidence
Mentioned
$ABVEF
Relevance
6/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ABVEFNeutralMed
01

Why it matters

This update adds a concrete step in the appeal process (retaining Dickinson Wright) and reiterates that the company still has outstanding periodic filing obligations, including an unfiled Annual Report on Form 20-F for the fiscal year ended January 31, 2026.

02

Market read

For traders, the key is whether the appeal and filing progress reduce perceived listing risk; the article provides procedural confirmation but no reinstatement outcome.

03

What to watch

Traders may be underweighting the unresolved Form 20-F (Listing Rule 5250(c)(1)) and the possibility that the council’s review hinges on filing completion and compliance history rather than advocacy.

Relevance 6/10Novelty 6/10Timing: ahead of the Nasdaq Listing and Hearing Review Council appeal process and within the prescribed response timeframe.

Background

Above Food previously requested review of Nasdaq’s prior delisting determination by the Nasdaq Listing and Hearing Review Council, citing delayed filings due to extenuating factors.

Company-level read

Ticker impact

$ABVEFNeutralMedium confidence
Context

Above Food says it engaged Dickinson Wright to represent it in its Nasdaq Listing and Hearing Review Council appeal after a prior delisting determination.

Expected impact

Likely modest, two-sided reaction in OTC liquidity as traders reassess odds of successful appeal and filing completion progress.

Evidence & confidence

The article discloses a concrete procedural step (legal representation) and reiterates outstanding 20-F filing obligations, which can influence perceived probability of regaining Nasdaq eligibility, but provides no decision, outcome, or new filing datapoint.

Market effects

Limited read-across to agricultural/food-tech peers; the main effect is on exchange-listing risk sentiment for small-cap issuers with filing delays.

Primarily impacts North American microcap listing-risk sentiment, with no clear regional macro linkage.

Low global relevance; this is an exchange-specific procedural update for a single issuer.

Counterpoint

The engagement of counsel may be largely procedural, and without evidence of completed filings or a favorable council decision, it may not materially change the probability of reinstatement.

Key entities

  • Above Food Ingredients Inc.

    OTC-listed agricultural and food technology company appealing Nasdaq’s delisting determination and working to complete outstanding filings.

  • Nasdaq Listing and Hearing Review Council

    The Nasdaq council that will review the company’s appeal of a prior delisting determination.

  • Dickinson Wright PLLC

    Law firm engaged to represent Above Food in the Nasdaq appeal.

  • Nasdaq Listing Qualifications Department

    The department that issued an additional expected notification regarding the company’s unfiled Form 20-F under Listing Rule 5250(c)(1).

Related articles

$NUTXMed

Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act

Nutex Health (NASDAQ: NUTX) commented on a Fifth Circuit ruling invalidating federal QPA calculation rules under the No Surprises Act, which the company says artificially deflated payments. The court ruled insurers cannot include non-negotiated 'ghost rates' and must include bonus payments in QPA calculations. Nutex Health expects this to lead to fairer upfront payments for providers. The ruling may impact the company's financials, but the timeline for new regulations is uncertain.

$LKFTMedAI 8/10

Lakefront Biotherapeutics: U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Lakefront Biotherapeutics (LKFT) announced that the U.S. FDA granted Orphan Drug Designation to gamgertamig for treating pemphigus, adding to prior designations for AIHA and ITP. The drug is in Phase 1b trials for autoimmune diseases, with expansion planned in 2027. Lakefront is developing gamgertamig with Gilead Sciences, aiming for registrational studies next year.

$BIIBLow

HSE to consider new offer from drug firm over Skyclarys

Biogen has submitted a new offer for its drug Skyclarys to be covered by Ireland's HSE, which will be discussed by the HSE Senior Management Team. The drug, approved by the EMA and FDA, treats Friedreich's ataxia and was previously rejected on cost grounds. Biogen disputes the NCPE's cost estimates, citing a €280,000 annual cost per patient and a €134m-€163m five-year budget impact.